| Date Filed | Type | Description |
| 04/14/2021 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 03/30/2021 |
GN
| Rafael Pharmaceuticals Crosses Enrollment of 150 Patients in Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (Devimistat) for Relapsed or Refractory Acute Myeloid Leukemia (AML) |
| 03/24/2021 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/18/2021 |
3
| CONKLING WILLIAM (Chief Commercial Officer) has filed a Form 3 on Rafael Holdings, Inc. |
| 03/17/2021 |
10-Q
| Quarterly Report for the period ended January 31, 2021 |
| 03/17/2021 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 03/11/2021 |
8-K
| Quarterly results |
| 03/11/2021 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 02/24/2021 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 02/12/2021 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/10/2021 |
GN
| LipoMedix Announces Manufacturing Agreement with ForDoz for Promitil® |
| 02/08/2021 |
RW
| Form RW - Registration Withdrawal Request: |
| 01/28/2021 |
8-K
| Other Events |
| 01/20/2021 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 01/19/2021 |
GN
| Rafael Pharmaceuticals to Present at B. Riley Securities Virtual Oncology Investor Conference |
| 01/19/2021 |
8-K
| Quarterly results |
| 01/14/2021 |
3
| JONAS RACHEL (Director) has filed a Form 3 on Rafael Holdings, Inc. |
| 01/13/2021 |
GN
| Rafael Pharmaceuticals to Present at 39th Annual J.P. Morgan Healthcare Conference |
| 01/07/2021 |
4
| PASCHE BORIS C (Director) has filed a Form 4 on Rafael Holdings, Inc.|
Txns:
| Granted 4,203 shares
@ $22.72, valued at
$95.5k
|
|
| 01/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 01/07/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 12/15/2020 |
10-Q
| Quarterly Report for the period ended October 31, 2020 |
| 12/15/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 12/15/2020 |
GN
| UPDATE - Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) |
| 12/15/2020 |
GN
| Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Acute Myeloid Leukemia (AML) |
| 12/11/2020 |
8-K
| Unregistered Sales of Equity Securities |
| 12/01/2020 |
GN
| Rafael Pharmaceuticals Partners with Sara's Cure and SARC for the Launch of Phase 2 Clinical Trial for CPI-613® (devimistat) in Combination with Hydroxychloroquine for Patients with Clear Cell Sarcoma of Soft Tissue |
| 11/23/2020 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 11/10/2020 |
GN
| Rafael Pharmaceuticals Receives FDA Fast Track Designation for CPI-613® (devimistat) for the Treatment of Pancreatic Cancer |
| 10/29/2020 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits |
| 10/29/2020 |
10-K
| Annual Report for the period ended July 31, 2020 |
| 10/29/2020 |
GN
| FDA Grants Rafael Pharmaceuticals Orphan Drug Designation for CPI-613® (devimistat) for Treatment of Soft Tissue Sarcoma |
| 10/20/2020 |
GN
| A New Phase 1 Study Began to Evaluate Rafael Pharmaceuticals' Lead Compound CPI-613®? (devimistat) for Patients With Pancreatic Cancer in Japan |
|